Drug Development

Combination Therapy Alzheimer's Treatments Targeted Therapy Eli Lilly Oral Medications Therapeutic Candidates Phase III Trials Antibody-Drug Conjugates Phase 3 Trials Late-Stage Trials Patient Outcomes Azelaprag Antibody Drug Conjugates Targeted Therapies Lenacapavir Lecanemab Phase 2 Trials Therapeutic Innovations SYM2081 Development Nanomedicine Formulations Cagrisema Results Heat Shock Proteins NHS Approval Phase 1b/2a Trials BCI and ERK Activity VEGF Inhibition Pain Relief Solutions CD40 Agonist Antibodies Biologic Drugs Amyloid Drugs V-DIFFERENCE Trial Gantenerumab Gene Therapy Regulatory Approval Baxdrostat Safety and Efficacy Antibody Therapy LUT014 ASITI-201 RAS Inhibitors COPD Treatments Therapeutic Strategies Immunotherapy Orphan Drug Designation Lecanemab Clinical Trials Hydrogels DKK1 Blockade FDA Approval Process Repurposed Medications AstraZeneca IgA Nephropathy Dementia Treatments Systemic Lupus Erythematosus Blenrep Long-acting Therapies Antibiotic Research Biotechnology Kinase Inhibitors Weight Loss Medications Innovative Therapies TAR-200 Rocatinlumab Morpholino Novartis and MMV Collaboration Experimental Drugs PP405 Trials Gedatolisib Safety Testing Neuropsychiatric Drugs Weight-loss Pills Phase 1/2 Trials Orforglipron Africa-led Trials Preclinical Testing Combination Treatments Infant Health Patient-Derived Xenografts AMT-130 NRTTI Research Gilead Sciences Diabetes Medications Sonelokimab Phase 3 Studies Regulatory Pathways Autoimmune Disorders Elinzanetant Phase II Trials Semaglutide Novo Nordisk Immunomodulatory Drugs Aficamten Eosinophilic Esophagitis Friedreich's Ataxia Ulcerative Colitis New Medications TROPION-Breast02 Trial Lymphoma Treatments Chronic Spontaneous Urticaria FDA Approval Efficacy and Safety